Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease in Adults 80-Years-of-Age and Older

Prog Cardiovasc Dis. 2018 Jan-Feb;60(4-5):562-564. doi: 10.1016/j.pcad.2017.12.006. Epub 2017 Dec 29.

Authors

G Blair Sarbacker¹, Kathleen A Lusk², Bethany Kalich²

Affiliations

¹ Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC, United States. Electronic address: gbsarback@presby.edu.
² Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX, United States.

PMID: 29291428
DOI: 10.1016/j.pcad.2017.12.006

No abstract available

Publication types

Letter

MeSH terms

Aged, 80 and over
Aspirin* / administration & dosage
Aspirin* / adverse effects
Cardiovascular Diseases / prevention & control*
Humans
Patient Selection
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / adverse effects
Primary Prevention / methods*
Risk Adjustment

Substances

Platelet Aggregation Inhibitors
Aspirin